No. 19-1131
Actavis Laboratories FL, Inc. v. Nalpropion Pharmaceuticals LLC
Amici (1)
Experienced Counsel
Tags: 35-usc-112 claim-construction federal-circuit patent-claims patent-law patent-law-35-usc-112 patent-specification patent-validity statutory-interpretation written-description written-description-requirement
Key Terms:
Antitrust Patent JusticiabilityDoctri
Antitrust Patent JusticiabilityDoctri
Latest Conference:
2020-05-21
Question Presented (from Petition)
Whether § 112 requires a patent's specification to contain a written description of all of the limitations of a patent's claims, not just a "substantially equivalent" disclosure.
Question Presented (AI Summary)
Whether § 112 requires a patent's specification to contain a written description of all of the limitations of a patent's claims, not just a 'substantially equivalent' disclosure
Docket Entries
2020-05-26
Petition DENIED.
2020-05-05
DISTRIBUTED for Conference of 5/21/2020.
2020-05-04
Reply of petitioner Actavis Laboratories FL, Inc. filed. (Distributed)
2020-04-15
Brief amicus curiae of Association for Accessible Medicines filed.
2020-04-15
Brief of respondent Nalpropion Pharmaceuticals LLC in opposition filed.
2020-03-13
Petition for a writ of certiorari filed. (Response due April 15, 2020)
Attorneys
Actavis Laboratories FL, Inc.
William McGinley Jay — Goodwin Procter, LLP, Petitioner
Association for Accessible Medicines
Matthew S. Hellman — Jenner & Block LLP, Amicus
Nalpropion Pharmaceuticals LLC
Dominick A. Conde — Venable LLP, Respondent